Cargando…
Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063439/ https://www.ncbi.nlm.nih.gov/pubmed/35434974 http://dx.doi.org/10.1002/2211-5463.13403 |
| _version_ | 1784699165021831168 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9063439 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90634392022-05-04 Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma FEBS Open Bio Corrigendum John Wiley and Sons Inc. 2022-04-18 /pmc/articles/PMC9063439/ /pubmed/35434974 http://dx.doi.org/10.1002/2211-5463.13403 Text en © 2022 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Corrigendum Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
| title | Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
| title_full | Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
| title_fullStr | Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
| title_full_unstemmed | Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
| title_short | Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
| title_sort | corrigendum to: regorafenib reverses hgf‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063439/ https://www.ncbi.nlm.nih.gov/pubmed/35434974 http://dx.doi.org/10.1002/2211-5463.13403 |